Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
The multicenter ROME trial randomized 200 patients to genomically matched therapies and 200 to standard care; objective responses were 35/200 versus 20/200 and median PFS was 3.5 versus 2.8 months, without a statistically significant overall survival difference. Different public treatments in selected cancers are not one hidden universal cure.